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Abstract
Background To prevent iatrogenic damage, transfusions of
red blood cells should be avoided. For this, specific and
reliable transfusion triggers must be defined. To date, the
optimal hematocrit during the initial operating room (OR)
phase is still unclear in patients with severe traumatic brain
injury (TBI). We hypothesized that hematocrit values
exceeding 28%, the local hematocrit target reached by the
end of the initial OR phase, resulted in more complications,
increased mortality, and impaired recovery compared to
patients in whom hematocrit levels did not exceed 28%.
Methods Impact of hematocrit (independent variable)
reached by the end of the OR phase on mortality and
morbidity determined by the extended Glasgow outcome
scale (eGOS; dependent variables) was investigated retro-
spectively in 139 TBI patients. In addition, multiple logistic
regression analysis was performed to identify additional
important variables.
Findings Following severe TBI, mortality and morbidity
were neither aggravated by hematocrit above 28% reached
by the end of the OR phase nor worsened by the required
transfusions. Upon multiple logistic regression analysis,
eGOS was significantly influenced by the highest intracra-
nial pressure and the lowest cerebral perfusion pressure
values during the initial OR phase.
Conclusions Based on this retrospective observational
analysis, increasing hematocrit above 28% during the initial
OR phase following severe TBI was not associated with
improved or worsened outcome. This questions the need for
aggressive transfusion management. Prospective analysis is
required to determine the lowest acceptable hematocrit
value during the OR phase which neither increases
mortality nor impairs recovery. For this, a larger caseload
and early monitoring of cerebral metabolism and oxygen-
ation are indispensable.
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Abbreviations
CPP Cerebral perfusion pressure
FFP Fresh frozen plasma
ICP Intracranial pressure
ICU Intensive care unit
RBC Red blood cells
TBI Traumatic brain injury
Introduction
Following severe traumatic brain injury (TBI), the injured
brain is highly vulnerable to additional insults. The most
deleterious secondary insults, which significantly increase
mortality following TBI, are hypotension and hypoxia [21].
Tissue hypoxia associated with signs of disturbed cerebral
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metabolism [29], excitotoxicity [29], and long-term psy-
chological impairment [26, 27] can be counteracted and
prevented by maintaining adequate cerebral perfusion and
improving tissue oxygen by additionally increasing paO2
[28] and transfusing red blood cells (RBCs) [18, 30].
To date, however, the optimal hemoglobin count remains
poorly defined [10, 19, 20]. In brain-injured patients,
hemoglobin of 10 g/dl (hematocrit 30%) is generally
regarded adequate [17], which can only be reached by
transfusing RBCs in patients with lower hematocrit levels.
Transfusions, in turn, are associated with complications
ranging from rare cases of transfusion-related viral and
bacterial infections to the more common problems due to
activated inflammatory, immunologic, and coagulation
pathways [2, 14, 23]. Liberal transfusions with hemoglobin
count >10–12 g/dl compared to 7–9 g/dl have been re-
peatedly associated with increased mortality and morbidity
reflected by infections, acute respiratory distress syndrome
(ARDS), multiorgan failure, congestive heart failure, myo-
cardial infarctions, and deep venous thrombosis in various
patient groups [2, 33]. Several large multi-center prospective
randomized and observational clinical trials performed in
heterogeneous patient groups, i.e., Transfusion Requirements
in Critical Care (TRICC) study, Anemia and Blood Trans-
fusion in Critical Care study, and Anemia and Blood Trans-
fusion in the Critically Ill study [3, 13, 41], showed that
increasing hemoglobin above 10 g/dl by transfusing RBCs
was associated with the worse outcome. This, in turn,
promoted the contemporary global restrictive transfusion
practice. Post hoc analysis [22] and retrospective studies
[8, 24] in TBI patients showed that the more restrictive
transfusion strategy (7–9 g/dl) was comparable to the liberal
strategy (10–12 g/dl) in terms of similar mortality or morbid-
ity during the intensive care unit (ICU) phase, thus justifying
lower hematocrit levels in these patients. In their retrospective
study, Carlson et al. could even show that prolonged duration
of hematocrit <30% during the ICU phase was associated
with improved outcome following TBI [1].
The optimal hemoglobin content, however, remains to be
defined especially during the acute phase in patients at risk
of insufficient oxygen supply as, e.g., patients with severe
TBI. To date, data investigating the impact of a specific
hemoglobin/hematocrit transfusion threshold following se-
vere TBI is limited to the ICU phase which is much more
stable compared to the highly unstable and unpredictable
emergency room (ER) and initial operating room (OR)
phase. This early phase is characterized by various
potentially deleterious influences, which can occur simul-
taneously as, e.g., anemia-inducing hemorrhages with
consecutive hypotension, hypovolemia, coagulopathy, aci-
dosis, as well as disturbed oxygenation with ensuing
hypoxemia and hypoxia. Thus, it remains unclear whether
a lower hematocrit is acceptable during the early phase and
which is the lowest but still tolerable and safe hematocrit
level.
Based on the general recommendations taken from the
TRICC study and the findings by Carlson et al. [1], we
hypothesized that patients with a hematocrit exceeding 28%
reached by the end of the OR phase fare worse than patients
with a hematocrit below 28%, in terms of increased
complications during the ICU, elevated overall in-hospital
mortality, and worse outcome determined by extended
Glasgow outcome scale (eGOS) after 6 months. For this,
we investigated 139 patients suffering from severe TBI who
were treated at the University Hospital from January 2004
to December 2006 who required intracranial pressure (ICP)
monitoring and who were transferred to the trauma surgical
ICU for further treatment.
Materials and methods
Inclusion criteria
The aims of the present retrospective study were to evaluate
the influence of different hematocrit levels reached by the
end of the initial OR phase on overall in-hospital mortality
and morbidity. Inclusion criteria for the present study were
patients suffering from severe TBI with and without
additional injuries requiring continuous ICP monitoring.
Patients succumbing within the first 24 h following TBI as
well as those patients on oral anticoagulants or platelet
inhibitors were excluded. Those patients who died within the
first 24 h were too severely injured, and their treatment was
already terminated in the OR before transferral to the ICU.
Following approval by the local ethics committee, which
waived the need for written informed consent for this
retrospective analysis, relevant information was transferred
from patient records to an anonymized data bank using
Microsoft Excel® and Microsoft Access®. Only patients
with a complete data set of the OR phase were considered
for subsequent analysis. Patients treated at the University
Hospital from January 1, 2004 to December 31, 2006 were
considered in the present analysis.
Standardized management in the emergency room (ER)
and operating room (OR)
Following initial hemodynamic and cardiopulmonary sta-
bilization, radiologic/ultrasonographic diagnostic measures
as well as surgical interventions according to the ATLS®
guidelines were performed. An ICP probe (Neurovent®,
Raumedic, www.raumedic.de) was inserted in the OR
adjacent to the ER during the ER/OR phase. Whenever
the ORs were occupied, surgical procedures were per-
formed in the equally equipped ER. Standard indications
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for ICP probe placement were typical trauma history
including secondary neurologic worsening, pathologic
neurological findings (Glasgow coma scale (GCS), ≤9),
and pathologic computed tomography (CT) findings. All
patients were intubated and subjected to continuous
analgesia and sedation using fentanyl (Sintenyl®) and
midazolam (Dormicum®) with intermittent muscle relaxa-
tion (pancuronium, Pavulon®). In addition to basic moni-
toring (ECG, SpO2, and etCO2), all patients received an
arterial and central venous line and a urinary catheter.
Hemodynamic stability was achieved by infusing crystal-
loids and colloids in addition to administration of norepi-
nephrine and dobutamine, whenever required. These
measures were guided by changes in lactate, urinary
production, heart rate, and central venous pressure. Trans-
fusion requirements were guided by hematocrit determined
by regular blood gas analysis and changes in coagulation
parameters (platelets, international normalized ratio (INR),
partial thromboplastin time (PTT), and fibrinogen) assessed
by routine laboratory analysis. According to the local
standards, hematocrit target was ≥28%, and platelets and
INR were maintained at levels ≥80,000/μl and ≤2, respec-
tively. Fibrinogen was normalized to values >1.5 g/l. With
these laboratory targets and the clinical picture including
actual blood loss, the amount and speed of transfusion as
well as the relation between RBCs and fresh frozen
plasmas (FFPs) were at the discretion of the individual
anesthesiologist.
Body core temperature measured by an esophageal
temperature probe was maintained between 34°C and
36°C. Hypothermia was only corrected at body core
temperature <34°C and signs of coagulopathy. Elevated
ICP was treated by increasing depth of sedation including
administration of thiopental, adding muscle relaxation,
adjusting paCO2, and by infusing mannitol, whenever
appropriate. In case of therapy refractory increases in ICP,
a further CT was performed, and surgical interventions
were evaluated (e.g., craniectomy).
Following the ER/OR phase, all patients were transferred
to the trauma surgical ICU where patients were treated
according to a standardized ICP/cerebral perfusion pressure
(CPP)-guided protocol aided by extended neuromonitoring
using BIS EEG and SjvO2 as previously described [25, 38].
Variables
Clinical data consisted of age, gender, injury severity
(injury severity score (ISS) and abbreviated injury scale
(AIS) head), number of injured organs, rate of pulmonary
complications consisting of functional pulmonary deterio-
ration determined by paO2/FiO2 ratio and development of
structural alterations (pneumonia, acute lung injury (ALI),
and ARDS), length of hospitalization on the ICU, and in-
hospital mortality. Neuropsychological recovery was
assessed by a standardized questionnaire, the eGOS, which
was mailed to the patients 6 months following trauma. In
case patients or their relatives did not return the question-
naire, an interview via telephone was performed.
During the ER/OR phase, changes in hematocrit, lactate,
base excess, paO2, paCO2, blood glucose, oxygenation ratio
(paO2/FiO2), mean arterial pressure, ICP, and CPP were
determined by assessing first, last, minimal, and maximal
values, respectively.
Blood loss as well as transfusion (RBC, FFP, platelets,
and coagulation factors), volume (cristalloids (Ringer
Lactate Baxter®) and colloids (Voluven 6%®; hydroxyethyl
starch 130/0.4)), and norepinephrine requirement were
investigated.
Changes in platelets, PTT, INR, leukocytes, and C-
reactive protein were assessed by evaluating the initial
values during the ER phase and upon arrival on the ICU.
Database
As previously described [25], the database was constructed
by entering data in predefined columns within a Microsoft
Excel® sheet for each individual patient. Then, all
individual sheets were transferred to one Microsoft Excel®
sheet containing data of all patients. This Microsoft Excel®
sheet was then imported into a Microsoft Access® database.
Data was entered by CF, SL, JS, and controlled for
plausibility and correctness by JFS and SL: following an
automated search for incorrect outliers within each column,
these values were then corrected by referring to the original
patient records.
Relative frequency was determined by first assessing the
absolute number of values found within predefined clusters
followed by expressing the number of values or incidences
per predefined cluster in percent to the absolute number of
all values of a certain parameter.
Statistical analysis
Graphical and statistical analysis was performed using
SigmaPlot® and SigmaStat®, respectively. Changes between
groups (hematocrit clusters) and within predefined hematocrit
cluster groups (survivors/non-survivors) were evaluated for
statistically significant differences using analysis of variance
on ranks with post hoc Dunn's test (multiple comparison) and
the Mann–Whitney rank sum test, respectively. Survival
probability was determined by log rank analysis (Kaplan–
Meier survival analysis with surviving patients being cen-
sored). Multiple logistic regression analysis was performed to
identify factors which independently predict outcome by
setting outcome as the dependent variable and the different
factors (worst values during ER/OR phase, transfusion and
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volume management during the ER/OR phase, and compli-
cations and transfusions during the ICU phase) as indepen-
dent variables. Differences were rated significant at a p<0.05.
Results
Demographic data
Investigated patients were of similar age, predominantly
male (78%), with the majority of patients presenting with
additional injuries (overall average: 67% multiply injured
patients). All patients had similar initial GCS scores (overall
average 6) and presented with similar injury scores (ISS and
AIS head; Tables 1 and 2). ISS was significantly increased in
patients requiring RBC transfusions (overall median 35 vs.
25; p<0.05) without a difference between surviving and
deceased patients. Deceased patients required craniectomy,
placement of pleural drainage, and laparotomy significantly
more often than surviving patients, regardless of transfusion
requirement and independent of hematocrit reached by the
end of the OR phase (craniectomy, 29% vs. 15%; pleural
drainage, 38% vs. 16%, laparotomy, 9% vs. 2%; p<0.05).
Changes in hematocrit
By the end of the initial OR phase, hematocrit was
significantly decreased in all patients compared to the
starting hematocrit, except in those transfused patients who
reached hematocrit >28% (Fig. 1). Within the predefined
hematocrit cluster >28%, non-transfused patients showed
significantly higher hematocrit levels compared to trans-
fused patients (Fig. 1). In patients in whom hematocrit
remained <28% by the end of the initial OR phase, there
was no difference between transfused and non-transfused
patients. Overall, by the end of the initial OR phase, there
was no difference in hematocrit values between surviving
and deceased patients (data not shown).
Blood loss and transfusion requirements
Blood loss was highest in deceased patients in whom
hematocrit remained <28% despite transfusions. The
hematocrit target set at >28% was successfully reached
in 45% of the patients requiring RBC transfusions.
Overall, 43% of the investigated patients received RBCs
during the initial OR phase. Depending on their blood
loss, patients required more transfusions (Table 1). Large
blood losses resulted in low hematocrit levels reached by
the end of the OR phase and lead to higher frequency of
transfusions; low blood losses were associated with higher
hematocrit levels and lower frequency of transfusions
(Fig. 2).
Laboratory signs of coagulopathy were observed
significantly more often in patients who required RBC
transfusions. Hypofibrinogenemia (<1.7 g/l) was the
Table 1 Characteristics in deceased and surviving traumatic brain
injury patients within different hematocrit clusters reached by the end
of the emergency room (ER)/initial operating room (OR) phase. These
patients received red blood cell transfusions. Differences are signifi-
cant between deceased and surviving patients within the hematocrit
clusters
Final hematocritER end <28% ≥28%
Deceased (N=16) Survivors (N=15) Deceased (N=11) Survivors (N=21)
N=31 N=32
Final hematocritER end (%) 24, 23 to 27 26, 22 to 27 30, 28 to 39 31, 28 to 34
Percent 48% 52% 34% 66%*
ISS 30, 16 to 66 37, 20 to 57 34, 25 to 50 38, 16 to 70
ICU length (days; median, range) 2.5, 2 to 12 17, 3 to 40 3, 2 to 23 16, 3 to 51
Blood loss (l) 3, 0.5 to 7* 1.5, 0.5 to 15 0.4, 0.1 to 6 1.5, 0.1 to 5
Colloids (l) 1.5, 0.5 to 3 1.5, 0.5 to 3 1.6, 0.5 to 6 1.5, 0.5 to 4.3
Cristalloids (l) 3.4, 1.3 to 7.5 2.4, 1.5 to 8.5 4, 0.9 to 18 3.2, 0.8 to 5
Balance (l) 3.9, −0.6 to 7.95 2.9, −5 to 7.6 2.5, 0 to 11 2.6, −2 to 11
Norepinephrine (μg/kg/min) 0.36, 0.07 to 1.9* 0.2, 0.03 to 1.6 0.2, 0.03 to 1.3* 0.12, 0.03 to 1.1
MAP min (mmHg) 70, 45 to 135 70, 35 to 90 65, 40 to 85 65, 25 to 95
ICP max (mmHg) 51, 28 to 104* 17, 2 to 105 48, 20 to 54* 16, 5 to 50
CPP min (mmHg) 59, 22 to 89 58, 35 to 74 60, 35 to 73 54, 30 to 80
ISS injury severity score, MAP mean arterial pressure, ICP intracranial pressure, CPP cerebral perfusion pressure, min minimum, max maximum
*p<0.05 (Mann–Whitney test)
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leading pathologic finding in 41% of transfused patients
vs. 7.9% in non-transfused patients, followed by throm-
bocytopenia (<80,000/μl) in 11% vs. 0%, PTT>40 s in
9.5% vs. 2.6%, and INR>2 in 2.6% vs. 1.6%.
Lab values and temperature
Overall, there were no significant differences between
lowest pH, highest lactate, lowest base excess, lowest
paO2, lowest paCO2, lowest and highest glucose, and
lowest paO2/FiO2 ratio across the investigated subgroups
(data not shown).
Table 2 Details in deceased and surviving traumatic brain injury
patients within different hematocrit clusters reached by the end of the
emergency room (ER)/initial operating room (OR) phase. These
patients did not receive any red blood cell transfusions. Differences
are significant between deceased and surviving patients within the
different hematocrit clusters
Final hematocritER end <28% ≥28%
Deceased (N=1) Survivors (N=5) Deceased (N=23) Survivors (N=47)
N=6 N=70
Final hematocritER end (%) 23 26, 25 to 27 36, 29 to 47 34, 28 to 47
Percent 17% 83% 33% 67%*
ISS 50 25, 14 to 34 25, 19 to 50 25, 9 to 57
Blood loss (l) 1.5 0.4, 0.4 to 1 0.2, 0 to 0.6 0.2, 0 to 1
Colloids (l) 0.9 1, 1 to 1.5 0.5, 0 to 2.5 0.6, 0.25 to 3
Crystalloids (l) 2 1.8, 1.5 to 2.2 1.6, 0.4 to 5 2, 0.2 to 4
Balance (l) 0.9 0.6, −2.7 to 1.8 0.6, −2.3 to 4.5 1, −1.8 to 3
Norepinephrine (μg/kg/min) 0.036 0.11, 0.02 to 0.2 0.06, 0 to 0.32 0.1, 0.02 to 0.72
MAP min (mmHg) 55 70, 65 to 80 80, 60 to 105 70, 45 to 100
ICP max (mmHg) 42 13, 6 to 28 22, 4 to 40 12, 2 to 50
CPP min (mmHg) 13 62, 54 to 70 69, 42 to 88 66, 32 to 90











































red blood cell transfusions/ hematocrit cluster (all patients) [%]
Fig. 2 Relative frequency of red blood cell transfusions (gray
symbols) decreased with increasing hematocrit levels reached by the
end of the emergency room phase. Mortality calculated for predefined
hematocrit clusters was lowest within hematocrit levels ranging from
28% to 36% (white bars)
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Fig. 1 Changes in hematocrit values at specific time points
(beginning and end of the initial operating room (OR) phase) in
transfused (gray bars) and non-transfused patients (white bars).
Changes in hematocrit were evaluated in predefined hematocrit
clusters determined by the end of the OR phase comparing <28%
and ≥28%. By the end of the OR phase, hematocrit was significantly
decreased (*p, 0.05, Mann–Whitney test)
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Mortality
Overall survival rate was 60% (83 survivors, 56 deceased;
total 139 patients; Tables 1 and 2). As suggested by Fig. 2,
mortality was lowest in patients reaching hematocrit values
between 28% and 30% compared to lower and higher
hematocrit levels (Fig. 2). However, calculated survival
probability (Kaplan–Meier analysis) excluded a significant
impact of transfusions and also excluded a significant
impact of different hematocrit levels reached by the end of
the ER phase with and without concomitant transfusions in
the different hematocrit clusters (Fig. 3). There was a trend
to lowest survival probability in transfused patients in
whom hematocrit remained <28% at the end of the OR
phase. A trend towards highest survival probability was
seen in patients in whom hematocrit exceeded 28% without
having been transfused. This effect, however, was lost after
4 weeks.
Morbidity determined by eGOS 6 months after severe TBI
Surviving patients showed a good recovery with a median
eGOS of 6.5 (all groups) determined 6 months after injury,
irrespective of transfusion requirements (data not shown).
Based on multiple logistic regression analysis, eGOS was
not influenced by the hematocrit reached by the end of the
initial OR phase or the lowest hematocrit level and was
neither influenced by the transfusion practice nor the
volume management. However, eGOS was dependent on
highest ICP and lowest CPP measured during the initial OR
phase as determined by multiple logistic regression analysis
(ICP max, p=0.007; CPP min; p=0.017).
ICP and CPP during the initial OR phase
Highest ICP values were measured in patients who died
later on compared to surviving patients (Tables 1 and 2).
CPP was lowest in deceased patients in whom hematocrit
remained <28% at the end of the initial OR phase (Tables 1
and 2).
Complications and duration of hospitalization
Overall, there was no significant difference in rate of
pulmonary complications assessed by pathologic paO2/
FiO2 values, irrespective of transfusion requirements and
reached hematocrit (data not shown).
Length of stay on the ICU in surviving patients was
similar in all patients, irrespective of transfusion require-
ments (Tables 1 and 2).
Deceased patients presented with a significantly shorter
length of hospitalization in the ICU compared to surviving
patients (Tables 1 and 2).
Fluid management, calculated fluid balance,
and norepinephrine administration
Highest amounts of fluids, calculated balance, and required
norepinephrine were found in deceased patients, mainly
within the hematocrit cluster <28% (Tables 1 and 2).
Patients not requiring transfusions also needed significantly
less volume administration and reached a significantly less
positive fluid balance by the end of the OR phase (Tables 1
and 2; p<0.05).
Discussion
Following severe TBI, contemporary transfusion practice
aimed at maintaining hematocrit ≥28% was not associated
with an increase in mortality as determined by the Kaplan–
Meier survival probability and was not associated with an
increased rate of pulmonary complications.
According to the present retrospective analysis, mortality
was strongly influenced by significantly increased ICP and
decreased CPP during the initial OR phase. Death in these
patients was always due to intractable ICP with signs of
severe brain stem damage due to supra- and infratentorial
herniation.
It is possible that a low hematocrit <28% could have
contributed to an increased ICP due to sustained cerebral
days after severe traumatic brain injury














1.0 < 28%, transfused; n = 31
< 28%, not transfused; n= 6
> 28%, transfused; n= 32
> 28%, not transfused; n= 70
Fig. 3 Log rank analysis of calculated survival probability (Kaplan–
Meier) excluded a significant influence of different hematocrit levels
above 28% and below 28% reached by the end of the initial operating
room phase on mortality following severe traumatic brain injury
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vasodilation as observed under experimental [6, 12] and
clinical conditions [5] or decreased oxygenation [11]. These
effects occur concentration-dependently [11] and aggravate
underlying brain damage [7, 12]. As shown by van Beek et
al., decreased hemoglobin (<8 g/dl) was associated with
poorer outcome following severe TBI [39]. Anemia was
also a function of severe arterial hypotension; and on
average, however, hemoglobin was similar in all patients,
regardless of outcome. Potentially aggravating effects,
however, cannot be differentiated by the present study
since (1) the patients within the low hematocrit group
already presented with a significantly decreased hematocrit
at the beginning of the OR phase due to ongoing
hemorrhage, and (2) ICP was not measured until after
specific treatment modalities had been started. Thus, we
cannot determine if the ICP had already been pathologically
elevated before or at the beginning of ongoing hemorrhage
and if ICP had been lower had the hematocrit been
increased more aggressively before inserting an ICP probe.
The facts that estimated ISS, blood loss, and transfusion
requirements were comparable in deceased and surviving
patients within the predefined hematocrit clusters reached
by the end of the OR phase strongly suggest that the
pathologically elevated ICP was a stronger determinant of
mortality than the transfusion practice or reached hemato-
crit. This is in line with results reviewed by Treggiari et al.
showing that persistently elevated ICP exceeding 20 mmHg
is associated with increased mortality and morbidity [36].
In addition to the significantly increased ICP, CPP had also
been significantly decreased in those patients who died later
on. Hypotension-induced insufficient cerebral perfusion
and oxygenation strongly increases mortality and morbidity
aggravated by additional insults as, e.g., hypoxia [21].
Anemia and secondary brain damage
Under physiologic conditions, cerebral oxygen supply can
be maintained in situations of decreased hematocrit to
prevent cerebral hypoxia [46] by increased cardiac output
and elevated cerebral oxygen extraction [17]. In addition to
systemic compensatory processes, local adaptive alterations
have been described. In this context, cerebral blood flow is
increased due to cerebral anemia-induced vasodilation [40].
Concomitantly, however, oxygen extraction is significantly
increased, and tissue oxygen is reduced [40], thereby
reflecting insufficient compensation with a sustained risk
for additional brain damage. Cerebral blood flow is
inversely proportional to blood oxygen content [34] and
viscosity [35] which are reduced by anemia. In healthy
volunteers [43, 44], induced hemodilution decreasing
hemoglobin to 7 g/dl (hematocrit 21%) can be compensat-
ed. Further decrease to 5 g/dl (15%), however, resulted in
neuropsychological impairment, which was reversed by
transfusing RBCs [43, 45]. In orthopedic patients, a
decrease in hematocrit to 24% (hemoglobin 8 g/dl) was
associated with signs of impaired cerebral oxygenation
[11]. Based on these findings, the lower acceptable
hematocrit should remain above 24% to avoid impairing
cerebral oxygenation and prevent induction of additional
brain damage as shown under experimental conditions [12].
Hare et al. could also demonstrate that underlying brain
damage increased hypoxemia-induced injury [12].
As suggested by several authors [1, 8, 24], reduction of
the transfusion threshold to a hematocrit level of 21–27%
(hemoglobin 7–9 g/dl) appears not to endanger TBI
patients. However, we must keep in mind that these
recommended values stem from stable and well-controlled
ICU conditions [1, 8, 18, 24, 30]. To date, we are still
lacking information regarding the initial unstable OR phase.
Thus, a general recommendation cannot be given at this
time point. Since the hematocrit target used at our hospital
was 28%, we cannot exclude that the lower level of optimal
hematocrit could even be lower. A prospective randomized
trial including refined neuropsychological testing is re-
quired to address this issue.
Under conditions of compromised microcirculation
which predominates the early phase following TBI as
shown experimentally [15, 32], an additional pathologic
influence mediated by transfused RBCs could aggravate
underlying injury. In this context, transfusion of RBCs
(28 days old) significantly impaired microcirculatory
perfusion and oxygenation and increased local inflamma-
tory response under experimental conditions [9, 37].
Whether these findings will also contribute to the activated
local thrombotic and inflammatory processes within the
injured brain [31, 32], thereby aggravating underlying
damage, remains to be determined under clinical condi-
tions. Although not significant, transfusions were associat-
ed with a trend to decreased survival during the first
4 weeks following severe TBI. This was mainly observed in
patients in whom hematocrit remained below 28% despite
transfusions (Fig. 3). It remains unclear if transfusions per
se or insufficient correction of hematocrit contributed to
this observed trend.
Limitations of the present study
The present retrospective study is purely observational and
is limited by its lack in controlled measures as the
transfusion trigger, time of delay, speed of RBC transfusion
as well as administration of FFPs, platelets, and coagulation
factors were at the discretion of the treating anesthesiolo-
gists, trauma surgeons, and neurosurgeons. Thus, the
present study does not allow to determine the additional
influence of administration of FFPs, platelets, and coagu-
lation factors or the impact of different RBC to FFP ratios
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which have been shown to significantly influence mortality
[4]. Furthermore, age of transfused RBCs, which have also
been shown to increase mortality in patients receiving
larger amounts of RBCs [42] and impair increase in
cerebral oxygen [16], was not specifically addressed in
the present study. Under emergency conditions in case of
ongoing hemorrhage, however, time delay due to selecting
only young RBCs (storage duration <2 weeks) is impossi-
ble. Due to individual and priority-dependent situations,
more specific monitoring of cellular deterioration with the
aim of defining an individual transfusion threshold by
using, e.g., ptiO2 and microdialysis during the OR phase is
merely impossible. This is due to time restraints, which are
immanent to the diagnostic and surgical procedures, and the
technical issues in terms of prolonged equilibration time,
which do not allow for physicians to wait for valid values
obtained by these techniques. During stable ICU condi-
tions, transfusion requirement can be guided by measuring
brain tissue oxygenation [18, 30]. Application of near-
infrared spectroscopy (NIRS) sensors and insertion of a
jugular bulb catheter, however, could prove helpful in
guiding and fine-tuning transfusion practice also under
extreme OR conditions.
Conclusions
As suggested by the present retrospective analysis, correc-
tion of hematocrit values above 28% during the initial OR
phase following severe TBI does not appear mandatory.
The lowest possible hematocrit level, however, must still be
determined. For this, more detailed monitoring of cerebral
metabolism and oxygenation during the initial OR phase by
using, e.g., jugular venous blood gas sampling or NIRS
technology are required to determine safe hematocrit levels,
identify detrimental hematocrit levels, and thus define
optimal and individual transfusion triggers.
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This paper addresses pertinent questions related with the acute,
presumably cranial and extracranial, surgical management of traumatic
brain injury (TBI) patients. How tolerable is the blood loss, due to
traumatic loss or bleeding during surgical procedures, either in terms
of blood volume or hemoglobin levels, without jeopardizing brain
oxygen supply and, consequently, outcome? In addition, which
objectives should be aimed for if the patient should be transfused?
The study design is very similar to the design of Clifton
hypothermia trial, as it divides TBI patients in two predefined clusters
based on the initial hematocrit level, using a hematocrit 28% as a cut-
off. Further exploring the similitude between these two studies, it also
evaluates the impact of blood transfusion or abstention of transfusion,
in both cohorts of patients.
This study accrues a significant number of patients, and the
statistical analysis is very robust, which altogether confers a
considerable power to the conclusions. As shown by previous
research, it demonstrates that substrate delivery, including oxygen,
may not be the main problem in TBI pathophysiology, reason why
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increasing hematocrit, and thus oxygen-carrying capacity, is not
necessarily associated with a decrease in morbidity and mortality.
In normal physiological conditions, the maximal capacity of
oxygen transport and unload to the brain is achieved at a hemoglobin
level around 10 mg/dl. In head-injured patients, this axiom is
probably questionable because the injury itself carries changes in
patterns of oxygen delivery and consumption, as well as cerebral
microcirculation. Many of these patients are either on increased
inspired fraction of oxygen or under the effect of drugs, as mannitol,
that have favorable rheological properties, or are sedated to improve
the flow/metabolism mismatch. Furthermore, the occurrence of
extracranial injuries that often requires surgical repair adds to
secondary brain lesions due to a higher incidence of hypoxia and
hypotension in these patients.
I suppose that some interesting conclusions can be drawn from this
study:
– It is better for head-injured patients if a blood transfusion is not
needed.
– Raising the hematocrit is not a technical problem, but it does not
translate into an increased outcome, probably because patients that
need a transfusion are those with higher incidence of hypoxia and
hypotension due to extracranial injuries or higher surgical blood loss.
The importance of the severity of primary injuries is expressed in
deceased patients with low hematocrit that fail to increase hematocrit
with transfusion.
– As shown in the prolific Fig. 3, mortality tends to be higher in
patients with low (28%) or in patients with higher (>36%) initial
hematocrit levels, as well as mortality is independent of blood
transfusion.
– The survival probability of non-transfused patient with <28%
hematocrit by the end of the OR phase is similar to those transfused
patients with >28% hematocrit, thus outshining the effect of
transfusion on raising the hematocrit.
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